Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes

Diabetes

Volumn 63, Issue 11, 2014, Pages 3835-3845

  Arif, Sefina ^a   Leete, Pia ^b   Nguyen, Vy ^a   Marks, Katherine ^a   Nor, Nurhanani Mohamed ^a   Estorninho, Megan ^a   Kronenberg Versteeg, Deborah ^a   Bingley, Polly J ^c   Todd, John A ^d   Guy, Catherine ^e   Dunger, David B ^e   Powrie, Jake ^f   Willcox, Abby ^b   Foulis, Alan K ^g   Richardson, Sarah J ^b   De Rinaldis, Emanuele ^h   Morgan, Noel G ^b   Lorenc, Anna ^h   Peakman, Mark ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^h ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; AUTOANTIBODY; AUTOANTIGEN;

ADOLESCENT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD; CHILD; CLUSTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PHENOTYPE; T LYMPHOCYTE; CD4+ T LYMPHOCYTE; FEMALE; MALE; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE;

EID: 84908632192     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0365     Document Type: Article

References (32)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383:69-82
2. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002;31:391-410
3. Kronenberg D, Knight RR, Estorninho M, et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLAA24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes 2012;61: 1752-1759
4. Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokinemediated β-cell death. Diabetes 2011;60:2112-2119
5. Skowera A, Ellis RJ, Varela-Calviño R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope [published correction appears in J Clin Invest 2009;119: 2844]. J Clin Invest 2008;118:3390-3402
6. Arif S, Tree TI, Astill TP, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004;113:451-463
7. Peakman M, Stevens EJ, Lohmann T, et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999;104:1449-1457
8. Greenbaum CJ, Beam CA, Boulware D, et al.; Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61:2066-2073
9. Vermeulen I, Weets I, Asanghanwa M, et al.; Belgian Diabetes Registry. Contribution of antibodies against IA-2b and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 2011;34:1760-1765
10. Campbell-Thompson ML, Atkinson MA, Butler AE, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia 2013;56:2541-2543
11. Long AE, Gillespie KM, Aitken RJ, Goode JC, Bingley PJ, Williams AJ. Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A-24 alleles at the onset of type 1 diabetes. Diabetes 2013;62:2067-2071
12. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 2010;95:3360-3367
13. Herold KC, Brooks-Worrell B, Palmer J, et al.; Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009;58:2588-2595
14. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155:173-181
15. R core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2012
16. Velthuis JH, Unger WW, Abreu JR, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010;59:1721-1730
17. Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol 2011;33: 9-21
18. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29:267-274
19. Tree TI, Lawson J, Edwards H, et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010;59:1451-1460
20. Linterman MA, Pierson W, Lee SK, et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med 2011;17:975-982
21. He J, Tsai LM, Leong YA, et al. Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013;39:770-781
22. Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355-360
23. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-1119
24. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005;54:1407-1414
25. Petrich de Marquesini LG, Fu J, Connor KJ, et al. IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 2010;53:1451-1460
26. Thompson WS, Pekalski ML, Simons HZ, et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B-cell compartment in human type 1 diabetes. Clin Exp Immunol 2014;177:571-585
27. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with newonset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62:3766-3774
28. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378: 487-497
29. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
30. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014; 37:1069-1075
31. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
32. Chan AC, Behrens TW. Personalizing medicine for autoimmune and inflammatory diseases. Nat Immunol 2013;14:106-109